Spinal cord stimulation
Ask the expert
The report presents a summary of the reimbursement situation for use of spinal cord stimulation. Indications include neuropathic and ischemic pain.
Clinical scenarios include trial insertion of electrodes and external stimulator, permanent implantation of spinal cord stimulator, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.
The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
- The Netherlands
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of the spinal cord stimulation devices include:
- Boston Scientific (Precision)
- Nevro (Senza)
- Stimwave (Freedom SCS)
- Abbot Vascular (BurstDR: Proclaim, Prodigy MRI IPG, St. Jude Medical Invisible Trial System; Eon)
- Medtronic (Intellis; SureScan: RestoreSenso, RestoreUltra, RestoreAdvanced, PrimeAdvanced)
- Saluda Medical (Evoke SCS System)
- Nuvectra (Algovita SCS)
- Med-Ally (VersaStim IPG Platform)
Table of content is not available at this moment.
In late September 2021, the Danish Health Data Agency (Sundhedsstyrelsen) has published the update of the Health Care Classification System (Sundheds-væsenets Klassifikations System, SKS). The most significant changes include: 31 new diagnosis codes and 14 procedure codes were added. The newly added procedure codes concern mainly pulmonary and airways area and neuromodulation procedures.Read more
In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.Read more
In April 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (repetitive short-pulse transscleral cyclophotocoagulation for glaucoma, deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults, and Melphalan chemosaturation for primary or metastatic cancer in the liver) and two Medtech Innovation Briefings (microINR for anticoagulation therapy and RenalSense Clarity RMS for acute kidney injury), and two clinical guidelines (for atrial fibrillation and chronic pain in over 16s).Read more
On April 20, 2021, the Dutch Healthcare Institute (ZIN) published an annual report on the progress of the conditional reimbursement program. In 2020, there were 13 ongoing projects under the program, six of which concerned medical technologies. Furthermore, in 2020, percutaneous transforaminal endoscopic discectomy for the treatment of lumbosacral radicular syndrome in lumbar disc herniation was included in the basic insurance package as regular care.Read more
In March 2021, the National Institute for Health and Care Excellence (NICE) published four new Interventional Procedure Guidance (transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids, extracorporeal whole liver perfusion, free-functioning gracilis transfer to restore upper limb function, cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy), two Medical Technologies Guidance (Danis stent for acute oesophageal variceal bleeding, Alpha-Stim AID for anxiety disorders), two Medtech Innovation Briefings (Sonata system for symptomatic uterine fibroids, Butterfly iQ+ for diagnostic ultrasound), and one Diagnostic Guidance (QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis). Also, five clinical guidelines were updated.Read more